Diarrhea News and Research

Latest Diarrhea News and Research

Imbruvica gets FDA approval for treatment of mantle cell lymphoma

The U.S. Food and Drug Administration today approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma, a rare and aggressive type of blood cancer.

13 Nov 2013

Synergy Pharmaceuticals starts first phase 3 clinical trial of plecanatide in CIC patients

Synergy Pharmaceuticals Inc. today announced the start of the first of two planned phase 3 clinical trials to confirm the safety and efficacy of plecanatide, its lead GC-C agonist and once-daily oral treatment, in adult patients with chronic idiopathic constipation.

13 Nov 2013

Results announced for Phase 3B/4 study of RAPAMUNE in kidney transplant patients

Pfizer Inc. (NYSE:PFE) announced today top-line results from a Phase 3B/4 study of RAPAMUNE® (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus-based therapy (TAC) to RAPAMUNE® 3 to 5 months after transplant.

12 Nov 2013

First generic versions of Aciphex delayed-release tablets get FDA approval for GERD treatment

The U.S. Food and Drug Administration today approved the first generic versions of Aciphex (rabeprazole sodium) delayed-release tablets, used to treat gastroesophageal reflux disease in adults and adolescents (ages 12 and up).

10 Nov 2013

Cumberland Pharmaceuticals net revenue decreases from $12.5 to $6.5 million

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced third quarter 2013 financial results.

5 Nov 2013

Experimental drug effective in treating patients with non-small cell lung cancer

An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death among men and women worldwide.

4 Nov 2013

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

Two targeted anticancer drugs used together after first-line chemotherapy for advanced stage non-small-cell lung cancer improve progression-free survival, the results of a large, prospective study show.

31 Oct 2013

Interim data from Phase 1B trial of an investigational anti-PD-1 immunotherapy in patients with previously-treated NSCLC announced by Merck

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the presentation of interim data from a Phase 1B trial (PN001) evaluating MK-3475, an investigational anti-PD-1 immunotherapy, in patients with previously-treated non-small cell lung cancer (NSCLC). The data were presented today by Dr. Edward Garon, Director of Thoracic Oncology, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, at the 15th World Conference on Lung Cancer in Sydney, Australia (Abstract #2416).

31 Oct 2013

Viropharma announces financial results for third quarter 2013

ViroPharma Incorporated reported today its financial results for the third quarter ended September 30, 2013. Net sales were $113 million for the third quarter ended September 30, 2013, as compared to $91 million in the same three months of 2012.

31 Oct 2013

Once-daily prescription medicine for COPD now available throughout the U.S.

GlaxoSmithKline plc and Theravance, Inc. today announced that BREO ELLIPTA, a once-daily prescription medicine for chronic obstructive pulmonary disease, is now available to pharmacies throughout the U.S.

30 Oct 2013

Canadian researchers contribute to the science of verotoxigenic E. coli and associated infections

Many Canadian scientists and clinicians were unsung heroes during the early years (1977-1983) of research unfolding around verotoxigenic E. coli (VTEC).

30 Oct 2013

Promising melanoma drug demonstrates potential for non-small cell lung cancer treatment

An experimental new cancer drug called MK-3475, which has shown dramatic promise for treating melanoma is also showing early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death of men and women worldwide.

30 Oct 2013

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

New findings from two integrated Phase 3 Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with STELARA- (ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared with placebo.

29 Oct 2013

Apremilast drug shows promise for Behcet's ulcers

Apremilast, an orally available small molecule modulating several inflammatory pathways, which is pending approval by the United States Food and Drug Administration, is showing promise in the treatment of mouth and genital ulcers in people with Behcet's syndrome, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in San Diego.

28 Oct 2013

Researchers identify obesity as possible risk factor for clostridium difficile infection

Researchers from Boston Medical Center and Boston University School of Medicine have identified obesity as a possible risk factor for clostridium difficile infection. These findings, which appear online in Emerging Infectious Diseases, may contribute to improved clinical surveillance of those at highest risk of disease.

25 Oct 2013

New flu vaccine offers better protection against circulating flu viruses

Last year's flu season was considered one of the strongest and deadliest in recent decades, according to the CDC. In preparation for this year's flu season, Concentra, a subsidiary of Humana Inc., offers a flu vaccine to provide greater protection against circulating flu strains.

23 Oct 2013

UTHealth researchers study how probiotic may help reduce gut inflammation in infants with colic

Researchers at The University of Texas Health Science Center at Houston have begun a study investigating whether a probiotic might be helpful in reducing gut inflammation in infants with colic.

17 Oct 2013

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation , today announced the results of the MPACT phase III clinical trial of ABRAXANE® in combination with gemcitabine were published online in the October 16th edition of the New England Journal of Medicine.

17 Oct 2013

Researchers develop simple blood test to identify patient with Irritable Bowel Syndrome

For the first time, a simple blood test may be the best way to determine if a patient is suffering from Irritable Bowel Syndrome, or another serious condition such as Inflammatory Bowel Disease, according to Cedars-Sinai physician researcher Mark Pimentel, MD, lead author of a multicenter clinical trial.

17 Oct 2013

IBS Treatment Center opens new clinic in Santa Monica, California

The IBS Treatment Center, which specializes in treating irritable bowel syndrome, announced the opening of a new clinic in Santa Monica, California, in late October. Conveniently located next to the UCLA Medical Center, this new branch of the clinic will provide a progressive approach to digestive health as well as easy access to treatment for patients previously without adequate care.

15 Oct 2013

Diarrhea News and Research

Latest Diarrhea News and Research

Imbruvica gets FDA approval for treatment of mantle cell lymphoma

Synergy Pharmaceuticals starts first phase 3 clinical trial of plecanatide in CIC patients

Results announced for Phase 3B/4 study of RAPAMUNE in kidney transplant patients

First generic versions of Aciphex delayed-release tablets get FDA approval for GERD treatment

Cumberland Pharmaceuticals net revenue decreases from $12.5 to $6.5 million

Experimental drug effective in treating patients with non-small cell lung cancer

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

Interim data from Phase 1B trial of an investigational anti-PD-1 immunotherapy in patients with previously-treated NSCLC announced by Merck

Viropharma announces financial results for third quarter 2013

Once-daily prescription medicine for COPD now available throughout the U.S.

Canadian researchers contribute to the science of verotoxigenic E. coli and associated infections

Promising melanoma drug demonstrates potential for non-small cell lung cancer treatment

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

Apremilast drug shows promise for Behcet's ulcers

Researchers identify obesity as possible risk factor for clostridium difficile infection

New flu vaccine offers better protection against circulating flu viruses

UTHealth researchers study how probiotic may help reduce gut inflammation in infants with colic

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Researchers develop simple blood test to identify patient with Irritable Bowel Syndrome

IBS Treatment Center opens new clinic in Santa Monica, California

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Diarrhea News and Research

Latest Diarrhea News and Research

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in